This week's FierceBiotech is brought to you by Rho.

Trouble viewing? Click here.


Rho-email-4.24.19

Hi Alayna,

Right-to-Try has been in the news a lot recently, but what does it actually mean for product sponsors? This white paper explores both Right-to-Try legislation and existing Expanded Access Programs, including:

  • Understanding sponsor responsibilities under these programs and when products may be eligible for these programs
  • Evaluating options such as treatment protocols, treatment INDs, and emergency use
  • Discussing development risks associated with participation in these programs

Download this white paper

Rho-button-download

 

If you no longer wish to receive communications from Rho, please opt out here.


Want to reach 137,000+ FierceBiotech subscribers with your own message?
Contact [email protected] or call 202-824-5074.



You are currently subscribed as [email protected]
If you no longer wish to receive communications from FierceBiotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400 
Washington, DC 20036